Arylpiperazines as fatty acid transport protein 1 (FATP1) inhibitors with improved potency and pharmacokinetic properties

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 9, 2013, Pages 2560-2565

  Matsufuji, Tetsuyoshi ^a   Ikeda, Mika ^a   Naito, Asuka ^a   Hirouchi, Masakazu ^a   Kanda, Shoichi ^a   Izumi, Masanori ^a   Harada, Jun ^a   Shinozuka, Tsuyoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Arylpiperazine; Fatty acid transport protein; High throughput screening; Microsomal stability

Indexed keywords

FATTY ACID TRANSPORT PROTEIN 1 INHIBITOR; FATTY ACID TRANSPORTER; IMIDAZOPYRIDINE DERIVATIVE; LONG CHAIN FATTY ACID COENZYME A LIGASE; PHENYLPIPERAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN INHIBITOR; THIAZOLE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DISTRIBUTION VOLUME; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; GASTROCNEMIUS MUSCLE; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID STORAGE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MUSCLE LEVEL; NONHUMAN; PHARMACOKINETICS; SOLEUS MUSCLE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; FATTY ACID TRANSPORT PROTEINS; HALF-LIFE; HUMANS; LIVER; MICE; MUSCLE, SKELETAL; PIPERAZINES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TRIGLYCERIDES;

EID: 84876148378     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.02.116     Document Type: Article

References (17)

1. J.E. Schaffer, and H.F. Lodish Cell 79 1994 427
2. N. Abumrad, C. Coburn, and A. Ibrahimi Biochem. Biophys. Acta 1441 1999 4
3. A. Bonen, D. Miskovic, and B. Kiens Can. J. Appl. Physiol. 24 1999 515
4. M. Kazantzis, and A. Stahl Biochem. Biophys. Acta 1821 2012 852
5. J.K. Kim, R.E. Gimeno, T. Higashimori, H.-J. Kim, H. Choil, S. Punreddy, R.L. Mozell, G. Tan, A. Stricker-Krongrad, D.J. Hirsch, J.J. Fillmore, Z.-X. Liu, J. Dong, G. Cline, A. Stahl, H.F. Lodish, and G.I. Shulman J. Clin. Invest. 113 2004 756
6. T. Matsufuji, M. Ikeda, A. Naito, S. Kanda, M. Izumi, J. Harada, H. Takakusa, M. Hirouchi, and T. Shinozuka Bioorg. Med. Chem. Lett. 22 2012 5067
7. The homology between human and mouse FATP1 is calculated to be 89% from NCBI reference sequence: NP-940982.1 (human FATP1), NP-036107.1 (mouse FATP1).
8. M. Chordia, L.J. Murphree, T.L. Macdonald, J. Linden, and R.A. Olsson Bioorg. Med. Chem. Lett. 12 2002 1563
9. M. Lang, M.H.-J. Seifert, K.K. Wolf, A. Aschenbrenner, R. Baumgartner, T. Wieber, V. Trentinaglia, M. Blisse, D. Vitt, N. Tajima, T. Yamashita, and H. Noda Bioorg. Med. Chem. Lett. 21 2011 5417
10. For the synthesis of 1-(5-fluoropyridine-2-yl)piperazine hydrochloride, see: Slassi, A.; Isac, M.; Arora, J.; Brown, D. PCT Int. Appl. 2007, WO 2007087135.
11. L. Almirante, A. Mugaini, D.N. Toma, A. Gamba, and W. Murmann J. Med. Chem. 13 1970 1048
12. J.D. Hlasta Tetrahedron Lett. 31 1990 5833
13. P. Desreumaux, and P. Chavatte Tetrahedron Lett. 63 2007 419
14. M. Bonnet, J.U. Flanagan, M.P. Hay, D.A. Chan, E.W. Lai, P. Nguyen, and A.J. Giaccia Bioorg. Med. Chem. 19 2011 3347
15. O. Ottoni, A. Neder, V. Dias, R. Cruz, and L. Aquino Org. Lett. 3 2001 1005
16. M. Zaidlewicz, A. Chechlowska, A. Prewysz-Kwinto, and A. Wojtczak Heterocycles 55 2001 569
17. G.P. Holloway, C.J. Chou, J. Lally, T. Stellingwerff, A.C. Maher, O. Gavrilova, M. Haluzik, H. Alkhateeb, M.L. Reitman, and A. Bonen Diabetologia 54 2011 1457